Immuno-oncology – Endpoints News

Ticker	Current Price	Change	Graph
IBB	105.21	1.95 (1.89%)
XBI	87.70	1.35 (1.56%)

#AACR18: Roche spotlights promising subgroup responses for lung cancer combo with Tecentriq

by John Carroll — on April 16, 2018 04:38 PM EDT

#AACR: Merck spotlights pivotal Keytruda/chemo data, hoping to break down skepticism to its frontline lung cancer duo

by John Carroll — on April 16, 2018 09:30 AM EDT
Updated: 10:00 AM

#AACR: Bristol-Myers tunes out static, broadcasts impressive results for Opdivo/Yervoy lung cancer combo

by John Carroll — on April 16, 2018 09:08 AM EDT
Updated: 10:00 AM

#AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda

by John Carroll — on April 15, 2018 09:30 AM EDT
Updated: 12:25 PM

Penn team spotlights a pilot ovarian cancer trial and survival rates for a personalized cancer vaccine

by Amber Tong — on April 13, 2018 07:56 AM EDT
Updated: 08:02 AM

Former Novo chairman Göran Ando joins the board as Tessa bags $50M in additional funding

by Amber Tong — on April 12, 2018 08:33 AM EDT

Merck racks up another win in wide-ranging PhIII Keytruda lung cancer study, this time as solo therapy

by John Carroll — on April 9, 2018 07:12 AM EDT
Updated: 08:05 AM

Constellation joins the mega-round club with $100M raise and plans to pursue cancer studies

by John Carroll — on April 9, 2018 06:00 AM EDT

Boehringer Ingelheim is thinking in blockbuster terms as it throws its hat into the ever-widening CD47 ring

by John Carroll — on April 4, 2018 02:18 PM EDT
Updated: April 5, 2018 09:31 AM

China’s biotech pipeline is brimming with PD-1/L1 checkpoints. Are they really needed?

by John Carroll — on March 26, 2018 03:51 PM EDT
Updated: 06:35 PM

Faster, more convenient Opdivo dosing schedules gives Bristol-Myers added edge in battle of the PD-1 blockbusters with Merck

by John Carroll — on March 6, 2018 09:57 AM EDT

Dana-Farber’s Laurie Glimcher helps launch a NYC biotech upstart with some key insights on immuno-oncology tech

by John Carroll — on February 27, 2018 07:29 AM EDT
Updated: 03:47 PM

Johns Hopkins spinout spotlights a showcase animal test for antibody-ligand I/O traps — matching checkpoints with a rein on Tregs

by John Carroll — on February 26, 2018 05:59 AM EDT
Updated: 06:00 AM

The I/O 2.0-combo tech race is on: Merck bags oncolytics player Viralytics in $394M buyout

by John Carroll — on February 21, 2018 05:31 AM EDT
Updated: 07:23 AM

Bristol-Myers lassos the next big thing in I/O, grabs ‘214 rights in a record $3.6B deal with Nektar

by John Carroll — on February 14, 2018 06:59 AM EDT
Updated: 10:05 AM

Skeptics pounce after Bristol-Myers scores an early hit on Opdivo-Yervoy combo for lung cancer

by John Carroll — on February 5, 2018 07:11 AM EDT
Updated: 03:15 PM

Video: How many PD-1/L1 drugs do we need? Where is immunotherapy headed? Watch Jay Bradner, Hervé Hoppenot, Ellen Sigal, David Berman, Gideon Blumenthal, and Aiman Shalabi discuss with Endpoints at #JPM18

by Endpoints Staff — on January 12, 2018 10:39 AM EDT
Updated: 10:59 AM

Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars

by John Carroll — on January 8, 2018 09:25 AM EDT

Celgene vet Barer lines up a $23M startup round for next-gen I/O tech out of Johns Hopkins

by John Carroll — on January 2, 2018 07:39 AM EDT

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs

by Brittany Meiling — on December 14, 2017 09:27 AM EDT
Updated: 09:32 AM

Category: Immuno-oncology